Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Quarterly Report)
Reporting Period: Quarter and Six Months ended September 30, 2015
Business Overview: DRL is a leading India-based pharmaceutical company operating through three primary segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company manufactures and markets prescription and over-the-counter finished pharmaceutical products, active pharmaceutical ingredients (APIs), and differentiated formulations globally.
Key Financial Metrics
All figures in Indian Rupees (Rs.) millions unless otherwise noted. Convenience translation to U.S. dollars provided at Rs.65.50 = U.S.$1.00.
| Metric | Six Months Ended Sep 30, 2015 | Six Months Ended Sep 30, 2014 | Three Months Ended Sep 30, 2015 | Three Months Ended Sep 30, 2014 |
|---|---|---|---|---|
| Revenues | Rs. 77,467 (U.S.$1,183) | Rs. 71,054 | Rs. 39,889 (U.S.$609) | Rs. 35,879 |
| Gross Profit | Rs. 47,415 (61.2% margin) | Rs. 41,830 (58.9% margin) | Rs. 24,468 (61.3% margin) | Rs. 20,986 (58.5% margin) |
| Profit Before Tax | Rs. 17,075 (U.S.$261) | Rs. 13,946 | Rs. 9,098 (U.S.$139) | Rs. 6,937 |
| Profit for the Period | Rs. 13,475 (U.S.$206) | Rs. 11,245 | Rs. 7,218 (U.S.$110) | Rs. 5,741 |
| Net Cash from Operating Activities | Rs. 19,992 (U.S.$305) | Rs. 9,013 | N/A | N/A |
| Cash and Cash Equivalents (Sep 30, 2015) | Rs. 6,681 (U.S.$102) | Rs. 5,394 (Mar 31, 2015) | N/A | N/A |
| Total Borrowings (Short + Long Term) | Rs. 37,073 (U.S.$566) | Rs. 43,126 (Mar 31, 2015) | N/A | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased by 9% (six months) and 11% (quarter) compared to the prior year periods. This was driven primarily by the Global Generics segment, which grew 11% (six months) and 15% (quarter), offset by a decline in the PSAI segment (-3% six months, -7% quarter).
- Profitability: Net profit increased by 20% (six months) and 26% (quarter). Gross margins improved across the board, with Global Generics margins rising to 67.4% (six months) and 67.3% (quarter) due to a favorable product mix and new product launches.
- Geographic Performance:
- North America: Strong growth of 23% (six months) and 32% (quarter) driven by new product launches (e.g., Esomeprazole, Memantine) and market share gains.
- India: Growth of 16% (six months) and 14% (quarter), aided by the acquisition of UCB's product portfolio.
- Emerging Markets: Significant decline of 21% (six months) and 22% (quarter), primarily due to currency devaluation and volume declines in Russia and Venezuela.
- Acquisitions: Completed the acquisition of a select portfolio of products from UCB India for Rs. 8,000 million in June 2015, contributing Rs. 451 million in revenue for the six-month period.
- Debt Reduction: Repaid long-term borrowings of Rs. 11,663 million during the six months, including full repayment of loans by Swiss and U.K. subsidiaries.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management continues to focus on expanding R&D in complex formulations and biosimilars. The company expects to continue reviewing opportunities for acquisitions of complementary technologies or product rights.
- Regulatory Risks (Subsequent Event): On November 5, 2015, the U.S. FDA issued a warning letter regarding cGMP deviations at API facilities in Srikakulam and Miryalaguda, and an oncology formulation facility in Duvvada. While production is not currently restricted, failure to correct issues could lead to refusal of admission of products into the U.S.
- Legal Contingencies:
- Nexium Litigation: Final approval of a settlement with class plaintiffs was granted in September 2015; the company will not make payments to class plaintiffs.
- Reclast/Zometa Litigation: Patent infringement suits by Novartis are ongoing; no provision has been made as the company believes the patents are invalid or not infringed.
- Child Resistant Packaging: Ongoing investigation by the U.S. CPSC and DOJ regarding packaging violations; no provision made as the likelihood of an unfavorable outcome is not yet probable.
- Venezuela Operations: Significant foreign exchange losses (Rs. 139 million for six months) were recorded due to the translation of monetary assets and liabilities at the SIMADI exchange rate (approx. 198 VEF/USD) rather than the preferential CENCOEX rate.
- Collaborations: Entered into a collaboration with Curis, Inc. for immuno-oncology targets and an asset purchase agreement with Hatchtech for a head lice product (Xeglyze).
Key Facts for Investor Verification
- FDA Warning Letter Impact: Verify the company's remediation plan and timeline for the November 2015 FDA warning letter to assess potential risks to U.S. generic drug approvals and shipments.
- Venezuela Currency Exposure: Monitor the stability of the Venezuelan Bolivar and the company's ability to repatriate funds, given the significant translation losses and restricted cash balances (Rs. 2,852 million).
- Acquisition Integration: Assess the revenue contribution and integration progress of the UCB product portfolio acquired in June 2015.
- Debt Structure: Note the shift in debt profile following the repayment of long-term Swiss and U.K. loans, leaving primarily short-term packing credits and a remaining long-term USD loan.
- Patent Litigation Status: Track the status of the Novartis (Reclast/Zometa) and Namenda antitrust litigations, as adverse outcomes could result in significant damages or market exclusions.